Moneycontrol
Get App
SENSEX NIFTY
you are here:

AstraZeneca Pharma Ltd.

BSE: 506820 | NSE: ASTRAZEN |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE203A01020 | SECTOR: Pharmaceuticals

Success
Alert
Please select a Day.
Info

BSE Live

Feb 20, 16:00
2802.00 -46.40 (-1.63%)
Volume
AVERAGE VOLUME
5-Day
3,006
10-Day
3,533
30-Day
2,139
1,372
  • Prev. Close

    2848.40

  • Open Price

    2843.80

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Feb 20, 15:55
2813.70 -33.85 (-1.19%)
Volume
AVERAGE VOLUME
5-Day
32,423
10-Day
35,636
30-Day
32,170
13,087
  • Prev. Close

    2847.55

  • Open Price

    2847.80

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    2813.70 (109)

ANNOUNCEMENTS ON AstraZeneca

  • Feb 20, 2020 18:05 Source: BSE

    AstraZeneca Pharma - Launch Of FDC Of Dapagliflozin 10Mg + Saxagliptin 5Mg Film Coated Tablets (QTERN®)

    We refer to our communication dated September 25, 2019 intimating the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®). With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has commenced the launch of QTERN® in India. FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).

  • Feb 20, 2020 18:05 Source: BSE

  • Feb 06, 2020 18:05 Source: BSE

    AstraZeneca Pharma - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    We are enclosing herewith Certificate dated February 5, 2020 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

  • Feb 04, 2020 17:31 Source: BSE

    AstraZeneca Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on February 4, 2020 in respect of the Unaudited Financial Results for the quarter ended December 31, 2019 approved in the Board Meeting of the Company held on February 3, 2020.

  • Feb 03, 2020 17:03 Source: BSE

    AstraZeneca Pharma - Outcome Of The Board Meeting Held On Monday, February 3, 2020

    At the Board meeting of the Company held on Monday, February 3, 2020 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2019. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 3, 2020 are enclosed herewith.

  • Jan 22, 2020 18:11 Source: BSE

    AstraZeneca Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on January 22, 2020 in respect of Board Meeting of the Company to be held on February 3, 2020.

  • Jan 21, 2020 17:08 Source: BSE

    AstraZeneca Pharma - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, February 3, 2020

    ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2020 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Monday, February 3, 2020 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2019 We would also like to inform you that the ''Trading Window'' remains closed for all Designated Persons, from December 16, 2019 to February 5, 2020 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

  • Jan 17, 2020 12:22 Source: BSE

    AstraZeneca Pharma - Shareholding for the Period Ended December 31, 2019

    AstraZeneca Pharma India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click here

  • Jan 10, 2020 17:06 Source: BSE

    AstraZeneca Pharma - Statement Of Investor Complaints For The Quarter Ended December 2019

    No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
    2020
    Name of the Signatory :- PRATAP RUDRA
    Designation :- Company Secretary and Compliance Officer

  • Jan 10, 2020 13:35 Source: NSE

    AstraZeneca Pharma India Limited

    AstraZeneca Pharma India Limited has informed the Exchange regarding 'Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018'.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Feb 03, 2020
Remark : Quarterly Results